Keywords: picoplatin, regimen, cuts, psa, half, hrpc, patients

Picoplatin regimen cuts PSA by half in 78% of HRPC patients; Ph II study

Article | 27 October 2008

Print This

The USA's Poniard Pharmaceuticals has reported positive incremental data from an ongoing Phase II trial of its lead drug candidate, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in